%0 Journal Article %T Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice %J Iranian Journal of Basic Medical Sciences %I Mashhad University of Medical Sciences %Z 2008-3866 %A Gheybi, Elaheh %A Salmanian, Ali Hatef %A Imani Fooladi, Abbas Ali %A Salimian, Jafar %A Mahmoodzadeh Hosseini, Hamideh %A Halabian, Raheleh %A Amani, Jafar %D 2018 %\ 01/01/2018 %V 21 %N 1 %P 26-32 %! Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice %K Breast Cancer %K HER2 %K MUC1 %K Recombinant antigen %K Vaccine %R 10.22038/ijbms.2017.25686.6335 %X Objective(s): Breast cancer is one of the most common cancers in the world and is on the increase. MUC1 and HER2 as tumor-associated antigens (TAAs) are abnormally expressed to some extent in 75–80% of breast cancers.  In our present research, a novel chimeric MUC1-HER2 (HM) protein was designed and used to study whether an immune response can be generated against these TAAs. In vitro analysis of the HER2-MUC1 construct confirmed the co-expression of MUC1 and HER2. Materials and Methods: BALB/c mice were immunized with this novel chimeric protein. The humoral immune response was assessed by enzyme-linked immunosorbent assay (ELISA). Then, BALB/c mice were injected subcutaneously 2×105 4T1-MUC1-HER2 tumor cells. Subsequently, tumor size and tumor necrosis measurements, MTT, cytokines assay and survival test were performed.  Results: The results implied a critical role of HER2 and MUC1 antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer. Conclusion: The results implied a critical role of HER2 and MUC1 antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer. %U https://ijbms.mums.ac.ir/article_9919_84248188e236e6b6f85909cbd6bb44df.pdf